Gilead misses key goal in NASH liver disease trial, shares sink

Share this post

Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company’s shares down 4.6 percent in after-hours trading.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply